Bioequivalence and Relative Bioavailability Studies to Assess a New Acalabrutinib Formulation That Enables Coadministration With Proton‐Pump Inhibitors

Acalabrutinib is a Bruton tyrosine kinase (BTK) inhibitor approved to treat adults with chronic lymphocytic leukemia, small lymphocytic lymphoma, or previously treated mantle cell lymphoma. As the bioavailability of the acalabrutinib capsule (AC) depends on gastric pH for solubility and is impaired...

Descripción completa

Detalles Bibliográficos
Autores principales: Sharma, Shringi, Pepin, Xavier, Burri, Harini, Zheng, Lianqing, Kuptsova‐Clarkson, Nataliya, de Jong, Anouk, Yu, Ting, MacArthur, Holly L., Majewski, Michal, Byrd, John C., Furman, Richard R., Ware, Joseph A., Mann, James, Ramies, David, Munugalavadla, Veerendra, Sheridan, Louise, Tomkinson, Helen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9804870/
https://www.ncbi.nlm.nih.gov/pubmed/36029150
http://dx.doi.org/10.1002/cpdd.1153

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9804870/
https://www.ncbi.nlm.nih.gov/pubmed/36029150
http://dx.doi.org/10.1002/cpdd.1153

Ejemplares similares